Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Tschirdewahn

Showing results (11-20 of 42) with videos related to

Pageof 5
Sort By:
Pathology Oncology Research : POR|January 22, 2011
Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancerTibor Szarvas, Tobias Jäger, Markus Becker, et al.
Human Pathology|March 25, 2014
Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancerTibor Szarvas, Henning Reis, Gero Kramer, et al.
The Prostate|April 11, 2016
Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancerTibor Szarvas, Henning Reis, Frank Vom Dorp, et al.
Urologia Internationalis|November 10, 2021
Retrograde Pyelography in the Presence of Urothelial Bladder Cancer Does Not Affect the Risk of Upper Tract Urothelial Cancer: A Retrospective Analysis of a Single-Centre CohortLukas Püllen, Cordelia Kaspar, Andrej Panic, et al.
Urologia Internationalis|December 16, 2024
Outcomes of Surgical Therapy for Local Recurrence and Oligometastatic Urothelial Carcinoma of the Bladder: 20 Years of Experience in a Tertiary CenterMulham Al-Nader, Ulrich Krafft, Christopher Darr, et al.
Urologia Internationalis|February 3, 2018
Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance ImagingMohammad Al-Bayati, Johannes Grueneisen, Susanne Lütje, et al.
Clinical Genitourinary Cancer|April 15, 2025
Impact of Extended Versus Limited Lymph Node Dissection on Surgical Outcome, Recurrence Patterns and Survival After Radical CystectomyMulham Al-Nader, Ulrich Krafft, Christopher Darr, et al.
Translational Andrology and Urology|July 18, 2020
Serum and tissue syndecan-1 levels in renal cell carcinomaChristian Niedworok, Carsten Kempkensteffen, Andreas Eisenhardt, et al.
Current Oncology (Toronto, Ont.)|January 20, 2023
Is an Endorectal Balloon Beneficial for Rectal Sparing after Spacer Implantation in Prostate Cancer Patients Treated with Hypofractionated Intensity-Modulated Proton Beam Therapy? A Dosimetric and Radiobiological Comparison StudyDalia Ahmad Khalil, Jörg Wulff, Danny Jazmati, et al.
Diagnostics (Basel, Switzerland)|October 29, 2020
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer PatientsCsilla Olah, Stephan Tschirdewahn, Michèle J Hoffmann, et al.
Pageof 5

Showing results (11-20 of 42) with videos related to

Sort By:
Pageof 5
Pathology Oncology Research : POR|January 22, 2011
Validation of circulating MMP-7 level as an independent prognostic marker of poor survival in urinary bladder cancerTibor Szarvas, Tobias Jäger, Markus Becker, et al.
Human Pathology|March 25, 2014
Enhanced stromal syndecan-1 expression is an independent risk factor for poor survival in bladder cancerTibor Szarvas, Henning Reis, Gero Kramer, et al.
The Prostate|April 11, 2016
Soluble syndecan-1 (SDC1) serum level as an independent pre-operative predictor of cancer-specific survival in prostate cancerTibor Szarvas, Henning Reis, Frank Vom Dorp, et al.
Urologia Internationalis|November 10, 2021
Retrograde Pyelography in the Presence of Urothelial Bladder Cancer Does Not Affect the Risk of Upper Tract Urothelial Cancer: A Retrospective Analysis of a Single-Centre CohortLukas Püllen, Cordelia Kaspar, Andrej Panic, et al.
Urologia Internationalis|December 16, 2024
Outcomes of Surgical Therapy for Local Recurrence and Oligometastatic Urothelial Carcinoma of the Bladder: 20 Years of Experience in a Tertiary CenterMulham Al-Nader, Ulrich Krafft, Christopher Darr, et al.
Urologia Internationalis|February 3, 2018
Integrated 68Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance ImagingMohammad Al-Bayati, Johannes Grueneisen, Susanne Lütje, et al.
Clinical Genitourinary Cancer|April 15, 2025
Impact of Extended Versus Limited Lymph Node Dissection on Surgical Outcome, Recurrence Patterns and Survival After Radical CystectomyMulham Al-Nader, Ulrich Krafft, Christopher Darr, et al.
Translational Andrology and Urology|July 18, 2020
Serum and tissue syndecan-1 levels in renal cell carcinomaChristian Niedworok, Carsten Kempkensteffen, Andreas Eisenhardt, et al.
Current Oncology (Toronto, Ont.)|January 20, 2023
Is an Endorectal Balloon Beneficial for Rectal Sparing after Spacer Implantation in Prostate Cancer Patients Treated with Hypofractionated Intensity-Modulated Proton Beam Therapy? A Dosimetric and Radiobiological Comparison StudyDalia Ahmad Khalil, Jörg Wulff, Danny Jazmati, et al.
Diagnostics (Basel, Switzerland)|October 29, 2020
Soluble Syndecan-1 Levels Are Associated with Survival in Platinum-Treated Bladder Cancer PatientsCsilla Olah, Stephan Tschirdewahn, Michèle J Hoffmann, et al.
Pageof 5